S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
NASDAQ:MIRM

Mirum Pharmaceuticals - MIRM Stock Forecast, Price & News

$25.00
+0.25 (+1.01%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$24.53
$25.37
50-Day Range
$18.42
$29.44
52-Week Range
$12.82
$30.55
Volume
293,868 shs
Average Volume
224,527 shs
Market Capitalization
$795.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.80

Mirum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.20 Rating Score
Upside/​Downside
102.4% Upside
$50.60 Price Target
Short Interest
Bearish
11.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
0.89mentions of Mirum Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$962,335 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.30) to ($2.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

210th out of 1,117 stocks

Pharmaceutical Preparations Industry

95th out of 550 stocks

MIRM stock logo

About Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals Stock Performance

MIRM Stock traded up $0.25 during midday trading on Friday, reaching $25.00. 293,868 shares of the company were exchanged, compared to its average volume of 224,527. Mirum Pharmaceuticals has a 1-year low of $12.82 and a 1-year high of $30.55. The stock's 50-day simple moving average is $22.77 and its 200 day simple moving average is $23.01. The company has a market cap of $795.88 million, a price-to-earnings ratio of -15.03 and a beta of 1.44.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.21. Mirum Pharmaceuticals had a negative net margin of 137.85% and a negative return on equity of 139.72%. The company had revenue of $17.48 million for the quarter, compared to analysts' expectations of $15.67 million. On average, research analysts anticipate that Mirum Pharmaceuticals will post -4.3 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on MIRM shares. HC Wainwright decreased their price target on shares of Mirum Pharmaceuticals from $69.00 to $63.00 and set a "buy" rating for the company in a research note on Thursday. SVB Leerink lifted their price target on shares of Mirum Pharmaceuticals from $50.00 to $52.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 24th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of "Buy" and an average price target of $50.60.

Insiders Place Their Bets

In other news, major shareholder James E. Flynn sold 38,478 shares of Mirum Pharmaceuticals stock in a transaction on Monday, June 6th. The shares were sold at an average price of $25.01, for a total value of $962,334.78. Following the transaction, the insider now directly owns 1,540,190 shares of the company's stock, valued at approximately $38,520,151.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 33.27% of the stock is owned by corporate insiders.

Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIRM Stock News Headlines

Here's Why Mirum Pharmaceuticals Stock Is Getting Hammered
Recap: Mirum Pharmaceuticals Q2 Earnings
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Down 5.2%
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 2.6%
See More Headlines
Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIRM Company Calendar

Last Earnings
8/04/2022
Today
8/13/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MIRM
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.60
High Stock Price Forecast
$74.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+107.2%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$-83,990,000.00
Net Margins
-137.85%
Pretax Margin
-154.82%

Debt

Sales & Book Value

Annual Sales
$19.14 million
Book Value
$3.38 per share

Miscellaneous

Free Float
21,243,000
Market Cap
$795.88 million
Optionable
Not Optionable
Beta
1.44














MIRM Stock - Frequently Asked Questions

Should I buy or sell Mirum Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares.
View MIRM analyst ratings
or view top-rated stocks.

What is Mirum Pharmaceuticals' stock price forecast for 2022?

5 brokerages have issued 1-year target prices for Mirum Pharmaceuticals' stock. Their MIRM share price forecasts range from $30.00 to $74.00. On average, they anticipate the company's share price to reach $50.60 in the next year. This suggests a possible upside of 102.3% from the stock's current price.
View analysts price targets for MIRM
or view top-rated stocks among Wall Street analysts.

How have MIRM shares performed in 2022?

Mirum Pharmaceuticals' stock was trading at $15.95 at the beginning of 2022. Since then, MIRM stock has increased by 56.8% and is now trading at $25.01.
View the best growth stocks for 2022 here
.

When is Mirum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our MIRM earnings forecast
.

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced its earnings results on Thursday, August, 4th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.21. The company earned $17.48 million during the quarter, compared to the consensus estimate of $15.67 million. Mirum Pharmaceuticals had a negative trailing twelve-month return on equity of 139.72% and a negative net margin of 137.85%.

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).

When did Mirum Pharmaceuticals IPO?

(MIRM) raised $75 million in an IPO on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

What is Mirum Pharmaceuticals' stock symbol?

Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIRM."

Who are Mirum Pharmaceuticals' major shareholders?

Mirum Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Franklin Resources Inc. (3.92%), Integral Health Asset Management LLC (0.56%), Russell Investments Group Ltd. (0.25%), Deutsche Bank AG (0.24%), Victory Capital Management Inc. (0.17%) and Calamos Advisors LLC (0.13%). Insiders that own company stock include Christopher Peetz, Edwin Jonathan Tucker, Ian Clements, James E Flynn, John A Maurer, Laurent Fischer and Pamela Vig.
View institutional ownership trends
.

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirum Pharmaceuticals' stock price today?

One share of MIRM stock can currently be purchased for approximately $25.01.

How much money does Mirum Pharmaceuticals make?

Mirum Pharmaceuticals (NASDAQ:MIRM) has a market capitalization of $818.83 million and generates $19.14 million in revenue each year. The company earns $-83,990,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does Mirum Pharmaceuticals have?

The company employs 137 workers across the globe.

How can I contact Mirum Pharmaceuticals?

Mirum Pharmaceuticals' mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The official website for the company is mirumpharma.com. The company can be reached via phone at (650) 667-4085 or via email at ir@mirumpharma.com.

This page (NASDAQ:MIRM) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.